Diana I. Brixner, PhD, RPh

In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems.

Panelists explore how payers choose between pharmacy and medical benefit designs for covering prescription digital therapeutics (PDTs), optimizing patient access and adoption, and discussing why the selected pathway was considered optimal for a specific PDT.

Health care professionals discuss the optimal timeline for collaborating with provider advocates to develop and implement protocols that facilitate patient access to prescription digital therapeutics (PDTs).

Diana Brixner, PhD, highlights the potential for prescription digital therapeutics (PDTs) to have impact in areas such as facilitating behavioral change for mental health conditions and strengthening adherence for complex disease states with intricate drug regimens.

Paul Jeffrey, PharmD, examines different contracting strategies that can help improve patient access to prescription digital therapeutics (PDTs).

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Paul Jeffrey, PharmD, presents the findings of a study, which investigated patient engagement and clinical outcomes associated with the use of prescription digital therapeutics (PDTs) in the treatment of substance use disorders, and discusses the need for further research to advance the efficacy and value of PDTs in this field.

The risk of discontinuation of oral anticoagulant therapy (both warfarin and direct oral anticoagulant therapies [DOACs]) among nonvalvular atrial fibrillation patients was high. Although the hazard ratio for discontinuation favors DOACs, it is unlikely that the small difference in discontinuation relative to warfarin is clinically meaningful.

Physician utilization during the year before the first indication of type 2 diabetes did not differ between Medicaid-covered and privately insured youth.

This review shows that insulin analogs are cost-effective versus human insulins based on pharmacoeconomic models and retrospective database analyses.